Grant received in 2024

DCCC has funded 200,000 DKK to the project.

In Denmark, prostate cancer is currently the most common cancer in men and the second most frequent cause of cancer related death with more than 1300 deaths per year. Prostate cancer becomes lethal when it spreads to other organs. Detecting prostate cancer at early stages is the best way to reduce the incidence of metastatic prostate cancer and mortality. Therefore, it is crucial to find methods for early detection of prostate cancer, which is the purpose of this initiative.

The initiative will establish a study to test a population based screening using prostate-specific antigen (PSA) and MRI. The aim is to investigate whether such a screening program can identify prostate cancer at an early stage, thereby reducing both disease progression and mortality. The study will also investigate whether screening could reduce overdiagnosis of less aggressive prostate cancer and ensure that only men who would benefit from treatment are diagnosed.

The funding from DCCC will enable the purchase of research resources to prepare the study protocol. Additionally, the funding will help build a national network through the organisation of protocol and project meetings and support applications for further funding.

Multidisciplinary organisation
The protocol originates from DaProCa.

Project stakeholder

• Mads Hvid Aaberg Poulsen, Associated Professor, Department of Urology, Esbjerg Hospital, University Hospital of Southern Denmark. Primary contact, mail: poulsen@rsyd.dk
• Søren Sørensen Madsen, Head of Department, Department of Urology, Esbjerg Hospital, University Hospital of Southern Denmark
• Peter Zvara, Consultant, Professor, Department for Urology, Odense University Hospital
• Esmaeil Nadimi, Professor, Department of Applied AI and Data Science, University of Southern Denmark
• Jes Søgaard, Director, Professor, Interdisciplinary Centre on Population Dynamics, University of Southern Denmark
• Michael Borre, Consultant, Professor, Department of Urology, Aarhus University Hospital
• Karina Dalsgaard Sørensen, Professor, MSc, Department of Molecular Medicine (MOMA), Aarhus University
• Lars Boesen, Consultant, Associated Professor, Department of Urology, Herlev Hospital
• Vibeke Berg Løgager, Consultant, Associated Professor, Department of Radiology, Herlev Hospital

Advisory board

• Hendrik Van Poppel, Professor, Head of the Department of Urology, University Hospitals Leuven, Belgium
• Mark Emberton, Professor, University College London Hospitals, United Kingdom, Dean at Faculty Medical Sciences, University College London

Klaus Brasso, Professor, Department of Urology, Rigshospitalet